Group items tagged

This FOA encourages circumscribed projects to generate fundamental knowledge of affective processes with key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer control continuum. The FOA solicits applications that involve collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

The main goal of this limited competition Funding Opportunity Announcement (FOA) is to continue the state-of the-art biobanking infrastructure and operations for early-stage and experimental clinical trials sponsored by the National Cancer Institute (NCI). The biobanking needs of the following NCI clinical trial programs will be supported: Experimental Therapeutics Clinical Trials Network (ETCTN), and Other NCI-supported early and experimental trials. Currently, this biobanking infrastructure supporting NCI early experimental clinical trials is part of a biobank serving primarily another NCI program, National Clinical Trials Network (NCTN). Through a separate U24 award under this FOA, the NCI aims to separate the existing ETCTN-serving biobanking infrastructure and operation from the current NCTN Biobank. This separated entity will be termed: Early-Phase and Experimental Clinical Trials Biospecimen Bank (also referred to as EET Biobank). Although the EET Biobank and the "parent" NCTN Biobank may be hosted in the same institution, they are expected to become independent operations with separate leaderships. EET Biobank will be responsible for collecting, processing, storing a variety of human specimens from patients with cancer who are participating in NCI-funded ETCTN and other NCI-supported early and experimental clinical trials. The responsibilities of EET Bank will also include maintenance of up-to-date specimen inventory and specimen distribution to qualified NCI-approved trial investigators and research laboratories.

The purpose of the initiative is to support multidisciplinary innovative exploratory and developmental research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US. Also listed under R01.

The THRIVE grant program is designed to provide seed funding for clinical and translational research and technology-based solutions that enhance our ability to predict when and how adverse effects may occur in patients who have received cancer treatment. Awards are made to investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the National Institutes of Health and/or other major granting institutions.

The Laura Bassi Scholarship was established by Editing Press in 2018 with the aim of providing editorial assistance to postgraduates and junior academics whose research focuses on neglected topics of study, broadly construed, within their disciplines.

The Rita Allen Foundation Scholars program funds basic biomedical research in the fields of cancer, immunology, and neuroscience, as well as pain through the Rita Allen Foundation Award in Pain. Rita Allen Foundation Scholars are distinguished by their bold approaches to basic scientific questions that address problems of global concern, as well as their potential for learning, leadership and collaboration.

The HERA Women's Cancer Foundation provides funds for a project focused on the cause, early detection, treatment, and/or understanding of ovarian cancer. This annual award provides $50,000 for a cross-disciplinary project that is collaborative in nature.  The application must identify two (or more) scientists with different yet complementary skills and explain how these skills will be synergistic in addressing the ovarian cancer problem.  Applications are now being accepted for the 2013 award.

The INSPIRE awards program was established to address some of the most complicated and pressing scientific problems that lie at the intersection of traditional disciplines.  It is intended to encourage investigators to submit bold, exceptional proposals that some may consider to be at a disadvantage in a standard NSF review process; it is not intended for proposals that are more appropriate for existing award mechanisms.

This fall, OARS will host a series of brown-bag workshops on navigating the NSF proposal process.  Workshops will be held select Tuesdays from noon to 1:00pm in Pearson 208.  You are welcome to attend any or all of the sessions.  Click through for dates and registration information.

Collect populations of native forbs, shrubs and grasses for BLM Seeds of Success program, and conduct germination studies of target species to understand native species requirements.

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate the design, conduct, and completion of clinical trials for improving prevention of human papillomavirus (HPV)-related cancers in human immunodeficiency virus (HIV)-infected individuals. To serve this goal, the FOA will support a network of international collaborative sites conducting meritorious and appropriately designed prevention clinical trials in the Latin American and Caribbean (LAC) region via a U54 Partnership Centers mechanism.

The Center to Reduce Cancer Health Disparities (CRCHD) of the National Cancer Institute (NCI), in partnership with the NCI Office of Cancer Centers (OCC), announces this opportunity to compete for administrative supplements to Cancer Center Support Grants (CCSGs; P30s) for NCI-designated Cancer Centers (CCs) to each recruit a Community Health Educator (CHE). The purpose of this administrative supplement funding opportunity is to support a strengthening of community outreach capacity by working through the National Outreach Network (NON). It is expected that NON CHEs, located at NCI-designated CCs, will enhance the development and dissemination of culturally appropriate, evidence-based cancer information to members of underserved communities including rural and racial/ethnic populations (e.g., African American/Black, American Indian/Alaska Native, Asian, Hispanic/Latino, Native Hawaiian/Other Pacific Islander) in a way that is tailored to their specific needs.

The FOA will focus on fusion oncoproteins found in tumors that have high risk of treatment failure and for which there has been little progress in identifying targeted agents. Responsive applications can focus on any fusion oncoprotein in pediatric solid tumors or on NUP98 fusion proteins that occur in young children with acute myelogenous leukemia (AML). However, greater preference will be given to applications focused on PAX-FOXO (alveolar rhabdomyosarcoma), C11orf95RELA (ependymoma), or NUP98 fusion proteins.

This Funding Opportunity Announcement (FOA) is a part of the National Cancer Institute (NCI) initiative intended to support Cancer Prevention Clinical Trials Network (CP-CTNet). The goals for the CP-CTNet include: Design and conduct early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis. These trials include phase 0 (microdosing), phase I (dose-finding), and phase II (preliminary efficacy) clinical trials; Characterization of the effects of these agents and interventions on their molecular targets, as well as on other biological events associated with cancer development (such as cell proliferation, apoptosis, growth factor expression, oncogene expression, immune response) and correlation of these effects with clinical endpoints. Development of further scientific insights into the mechanisms of cancer prevention by the agents examined, including the development of novel potential markers as determinants of response.

The purpose of this FOA is to develop, test, and evaluate interventions and implementation approaches, or adapt existing approaches, to improve patient/provider/family risk communication and decision making for individuals and families with an inherited susceptibility to cancer.

Funds small, short-term studies on leading women's health concerns including cardiovascular disease, female cancers, the role of hormones in disease and stage-of-life health issues such as pregnancy and menopause